Pulmonary Arterial Hypertension - A small market gets big attention

Questions: Discounts, Updates etc.

Price: $7,600.00

Publication Date: 2006-02-01

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Datamonitor expects the global pulmonary arterial hypertension (PAH) market to grow from $636m in 2004 to just over $2 billion by 2014, as new product and formulation launches in the US and a healthy late-stage pipeline drive sales growth. With this increased interest, combined with increased awareness and R&D activity, treatment for this orphan disease is set to enter a new era


Scope

  • Comprehensive analysis of the attractiveness of the PAH market based on epidemiology, unmet needs, R&D activity and potential revenue
  • Analysis of clinical trial data and market potential of the recently launched PAH specific therapies and compounds in late stage development
  • Detailed comparative analysis of all PAH specific compounds in terms of efficacy, drug delivery, target audience and cost
  • In-depth profiles of current treatments, including PAH specific and non-PAH specific compounds


    • Report Highlights
    PAH is a rare condition with an estimated 146,000 sufferers across the US, EU and Japan. However, despite this low patient population, this market has attracted R&D investment due to the high unmet needs and high treatment values per patient

    Despite low patient numbers, it is estimated that up to 75% of these patients are not recognized and treated with therapy, creating significant room for growth in the number of patients treated with PAH therapies over the next decade

    Actelion's Tracleer, the first oral therapy approved by the FDA in 2001, will come under significant competitive pressure over the next three years. With approval for Encysive's Thelin expected in March 2006 and Myogen's ambrisentan expected to launch in 2007, an intense marketing battle is expected as each company fights for market share


    Reasons to Purchase

  • Assess the attractiveness of the PAH market for R&D investment and/or in-licensing activity
  • Gain insight into the current challenges and commercial opportunities associated with this devastating disease
  • Access key opinion leader views on the relative merits and weaknesses of current and future treatments for PAH, and the unmet needs therein

    • Table of Contents

    Other users found this report page using the following search terms: Pulmonary Arterial Hypertension PAH hypertension market pulmonary pah oral prevalence treprostinil arterial cost revatio

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.